Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Dermatologic 1

Conditions

Pancreatic Neoplasms 2Uveal Melanoma 1Neoplasms 1Melanoma 1Histiocytic Neoplasms 1Glioma 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1

Interventions

Gemcitabine 406Oxaliplatin 131Fluorouracil 125130-nm albumin-bound paclitaxel 108Capecitabine 100Albumin-Bound Paclitaxel 90Leucovorin 88Irinotecan 87Radiotherapy 76Radiosurgery 64Taxes 63Cisplatin 56Erlotinib Hydrochloride 44Drug Therapy 42folfirinox 40Magnetic Resonance Spectroscopy 39pembrolizumab 35Blood Specimen Collection 33S 1 (combination) 31Pancreaticoduodenectomy 31Docetaxel 31Nivolumab 30Bevacizumab 30Biopsy 26Surgical Procedures, Operative 25Cyclophosphamide 25irinotecan sucrosofate 24Specimen Handling 24Radiation 22Standard of Care 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Pancreatic Neoplasms × ulixertinib × Clear all
NCT03454035 2025-09-11

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

UNC Lineberger Comprehensive Cancer Center

Phase 1 Recruiting
45 enrolled
DermatologicGastrointestinal

Melanoma, Neoplasms, Pancreatic Neoplasms

NCT02608229 2021-04-21

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Washington University School of Medicine

Phase 1 Terminated
18 enrolled 14 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡